High-risk extranodal natural killer/T-cell lymphoma patients could benefit more from allogeneic hematopoietic stem cell transplantation as consolidation: A real-world multicenter analysis in China
Objective: Both allogeneic hematopoietic stem cell transplantation (allo-HSCT) and autologous HSCT (ASCT) are important therapies for extranodal natural killer/T-cell lymphoma (ENKTCL); however, no large-scale, multicenter study has compared the efficacy and safety berween allo-HSCT and ASCT in these parients. Our multicenter, real-world study aimed to evaluate the outcomes of allo-HSCT vs. ASCT as consolidation in ENKTCL patients who had achieved a complete response (CR) or partial response (PR).<br /> Methods: This was a multicenter, retrospective study with nine hospitals in China, and 114 patients with ENKTCL were enrolled. Sixty patients received ASCT and 54 received allo-HSCT. The primary outcome was progression-free survival (PFS). In the sensitivity analysis, propensity score matching (PSM) analyses were conducted to adjust for baseline prognostic factors. Landmark analysis were conducted to minimize immortal-time bias.<br /> Results: Patients in the allo-HSCT group presented with more adverse prognostic factors. Allo-HSCT group showed a significantly better PFS and a lower disease progression rate compared with ASCT group in patients with Ann Arbor stage III/TV disease (PFS: 100% vs. 82.0%, P = 0.023 disease progression rate: 0 vs. 25.4%, P = 0.024 ) those with intermediate/high prognostic index of natural killer lymphoma (PINK) scores (PFS: 100% nu tau. 84.4%, P = 0.034 disease progression rate: 0 vs. 22.1%, P = 0.034% those with intermediate/high international prognostic index (IPI) scores (PFS: 100% vs. 82.0%, P = 0.038 disease progression rate: 0 vs. 25.4%, P = 0.038 ) s or those receiving HSCT at PR (PFS: 100% vs. 50%, P = 0.046 disease progression rate: 0 vs. 50%, P = 0.046 ) at the 1.5-4.0 follow-up. In multivariate analysis, receiving ASCT was significantly associated with a poorer PFS [hazard ratio (HR) = 2.23 P = 0.038 ] and overall survival (OS) (HR-2.45, P = 0.045 ) In the sensitivity analysis, patients receiving allo-HSCT showed a significantly better PFS (70.3% vs. 39.1%, P = 0.039 ) OS (73.9% vs. 42.0%, P = 0.044 ), and a lower disease progression rate (22.6% vs. 57.0%, P = 0.017 ) compared with those receiving ASCT after propensity score matching.<br /> Conclusions: ENKTCL patients with high-risk characteristics could benefit more from allo-HSCT as<br /> consolidation.
基金：
Talent development plan for the future in Medical-Engineering Integration by BRA-CDCHE; National Key Research and Development Program of China [2022YFC2502600, 2022YFC2502606]; Beijing Natural Science Foundation [Z230016]; National Natural Science Foundation of China [82570262, 82170206, 82170208]; Science and Technology Plan of Tongzhou District [KJ2024CX045]; Shanghai Municipal Health Commission Project of Disciplines of [20224Z0022]
第一作者机构：[1]Peking Univ, Peking Univ Peoples Hosp, Peking Univ Inst Hematol, Natl Clin Res Ctr Hematol Dis,Beijing Key Lab Cell, Beijing 100044, Peoples R China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Wang Yuewen,Xia Yi,Gu Zhenyang,et al.High-risk extranodal natural killer/T-cell lymphoma patients could benefit more from allogeneic hematopoietic stem cell transplantation as consolidation: A real-world multicenter analysis in China[J].CHINESE JOURNAL OF CANCER RESEARCH.2025,37(5):doi:10.21147/j.issn.1000-9604.2025.05.03.
APA：
Wang, Yuewen,Xia, Yi,Gu, Zhenyang,Chang, Yu,Yang, Lei...&Mo, Xiaodong.(2025).High-risk extranodal natural killer/T-cell lymphoma patients could benefit more from allogeneic hematopoietic stem cell transplantation as consolidation: A real-world multicenter analysis in China.CHINESE JOURNAL OF CANCER RESEARCH,37,(5)
MLA：
Wang, Yuewen,et al."High-risk extranodal natural killer/T-cell lymphoma patients could benefit more from allogeneic hematopoietic stem cell transplantation as consolidation: A real-world multicenter analysis in China".CHINESE JOURNAL OF CANCER RESEARCH 37..5(2025)
